Patents Represented by Attorney Stephen D. Prodnuk
  • Patent number: 8247411
    Abstract: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: August 21, 2012
    Assignee: Pfizer Inc
    Inventors: Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
  • Patent number: 8217057
    Abstract: This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Grant
    Filed: November 23, 2006
    Date of Patent: July 10, 2012
    Assignee: Pfizer Inc.
    Inventors: Jingrong Jean Cui, Michelle Bich Tran-Dubé
  • Patent number: 8217036
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 10, 2012
    Assignee: Wyeth LLC
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • Patent number: 7179910
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Huiping Guan, Congxin Liang, Li Sun, Peng Cho Tang, Chung Chen Wei, Tomas Vojkovsky, Qingwu (Alan) Jin, Paul M. Herrinton, Michael A. Mauragis
  • Patent number: 7125905
    Abstract: The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 24, 2006
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Li Sun, Chung Chen Wei, Shahrzad Shirazian, Congxin Liang, Tomas Vojkovsky, Asaad S. Nematalla, Michael Hawley
  • Patent number: 6884890
    Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: April 26, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Robert Steven Kania, Steven Lee Bender, Allen J. Borchardt, Stephan James Cripps, Ye Hua, Michael David Johnson, Theodore Otto Johnson, Jr., Hiep The Luu, Cynthia Louise Palmer, Siegfried Heinz Reich, Anna Marie Tempczyk-Russell, Min Teng, Christine Thomas, Michael David Varney, Michael Brennan Wallace, Michael Raymond Collins
  • Patent number: 6869962
    Abstract: The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: March 22, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael Collins, Stephan Cripps, Judith Deal, Robert Steven Kania, Jihong Lou, Mingying He, Cynthia Louise Palmer, William Henry Romines, III, Ru Zhou
  • Patent number: 6794146
    Abstract: A 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: September 21, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michele A. McTigue, Chris Pinko, Camran V. Parast, Michael R. Gehring, Chen-Chen Kan, Krzysztof Appelt, John A. Wickersham, Richard E. Showalter, Anna M. Tempcyzk-Russell, Barbara Mroczkowski, Jesus E. Villafranca
  • Patent number: 6784285
    Abstract: A 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: August 31, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michele A. McTigue, Chris Pinko, Camran V. Parast, Michael R. Gehring, Chen-Chen Kan, Krzysztof Appelt, John A. Wickersham, Richard E. Showalter, Anna M. Tempcyzk-Russell, Barbara Mroczkowski, Jesus E. Villafranca
  • Patent number: 6753416
    Abstract: A 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR), a key enzyme in angiogenesis, has been determined in an unliganded, phosphorylated state. This protein construct, contains a modified catalytic linker and has comparable in vitro kinase activity to constructs containing the entire KID. The resulting construct retains comparable in vitro kinase activity to that of the wild-type KID, and more importantly, allows complete crystallization of the protein such that it may be characterized by X-ray crystallography. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions.
    Type: Grant
    Filed: August 28, 2001
    Date of Patent: June 22, 2004
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michele A. McTigue, Chris Pinko, Camran V. Parast, Michael R. Gehring, Chen-Chen Kan, Krzysztof Appelt, John A. Wickersham, Richard E. Showalter, Anna M. Tempcyzk-Russell, Barbara Mroczkowski, Jesus E. Villafranca
  • Patent number: 6642316
    Abstract: Improved thermoplastic polymer blend compositions comprising an isotactic polypropylene component and an alpha-olefin and propylene copolymer component, said copolymer comprising crystallizable alpha-olefin sequences. In a preferred embodiment, improved thermoplastic polymer blends are provided comprising from about 35% to about 85% isotactic polypropylene and from about 30% to about 70% of an ethylene and propylene copolymer, wherein said copolymer comprises isotactically crystallizable propylene sequences and is predominately propylene. The resultant blends manifest unexpected compatibility characteristics, increased tensile strength, and improved process characteristics, e.g., a single melting point.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: November 4, 2003
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Sudhin Datta, Charles Cozewith, Periagaram Periagaram, Edmund J. Stachowski
  • Patent number: 6608000
    Abstract: The invention generally relates to a metallocene-based, olefin polymerization catalyst system. The easily processible polymer product has a broad molecular weight distribution, a high molecular weight, and a narrow composition distribution. The catalyst system comprises a first component with a Group-4-6 metal bonded to cyclopentadienyl-containing rings having at least two substituents bonded to the rings in the same position; a second component comprising a Group-4-6 metal bonded to cyclopentadienyl-containing rings having at least two substituents bonded to the rings; and a third component comprising a Group-4-6 metal bonded to cyclopentadienyl-containing rings where one of the rings is substituted identically to the first component and another is substituted identically to the second component. When the substituents of the first and second components are the same, they are bonded to the first component rings at positions different from the bonding positions of the second component rings.
    Type: Grant
    Filed: September 13, 2000
    Date of Patent: August 19, 2003
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Robert Lee Bamberger, Moses Olukayode Jejelowo
  • Patent number: 6569963
    Abstract: A process for controlling the MWD of a broad or bimodal resin in a single fluid bed reactor using a mixed catalyst composition containing a bimetallic catalyst and a make-up catalyst of at least one metallic component of the bimetallic catalyst. The bimetallic catalyst, which is formed with at least one metallocene of a transition metal, produces broad or bimodal molecular weight distribution polyolefin resin whose composition depends on the ratio of the concentration of the two catalyst components producing the HMW/LMW components. The make-up catalyst consisting of a single metal component is added in proportion necessary to make-up the deficiencies in the amount of the HMW/LMW component. The type of make-up catalyst added depends on whether increase of the HMW or LMW component produced by the bimetallic catalyst is sought. The mixed catalyst compostion may be fed into the reactor as a mixture or through separate catalyst ports of the reactor.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: May 27, 2003
    Assignee: ExxonMobil Oil Corporation
    Inventors: Thomas E. Nowlin, Sandra D. Schregenberger, Pradeep P. Shirodkar, Grace O. Tsien
  • Patent number: 6509431
    Abstract: The invention relates to alteration of a linear low density polyethylene which is ordinarily free of long chain branching to introduce long chain branching into the polymer.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: January 21, 2003
    Assignee: ExxonMobil Oil Corporation
    Inventors: Robert Phillip Duttweiler, Michael Joseph Krause, Frederick Yip-Kwai Lo, Shih-May Christine Ong, Pradeep Pandurang Shirodkar
  • Patent number: 6503637
    Abstract: A film comprising a blend of: i) a homopolymer of ethylene having a Mw/Mn of 3 or a copolymer of ethylene and up to 50% weight % of a C3 to C20 olefm, the copolymer having a CBDI of 50% or more; ii) a homopolymer of propylene or a copolymer of propylene and up to 50 weight % of a comonomer selected from the group consisting of ethylene and C4 to C20 alpha-olefms; and iii) a polymer produced in a high pressure process using a free radical initiator.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: January 7, 2003
    Assignee: Exxon Mobil Chemical Patents Inc.
    Inventor: Achiel Jos Van Loon
  • Patent number: 6492473
    Abstract: The invention encompasses a mixed transition metal olefin polymerization catalyst system suitable for the polymerization of olefin monomers comprising one late transition metal catalyst system and at least one different catalyst system selected from the group consisting of late transition metal catalyst systems, transition metal metallocene catalyst systems or Ziegler-Natta catalyst systems. Preferred embodiments include at least one late transition metal catalyst system comprising a Group 9, 10, or 11 metal complex stabilized by a bidentate ligand structure and at least one transition metal metallocene catalyst system comprising a Group 4 metal complex stabilized by at least one ancillary cyclopentadienyl ligand. The polymerization process for olefin monomers comprises contacting one or more olefins with these catalyst systems under polymerization conditions.
    Type: Grant
    Filed: August 8, 2000
    Date of Patent: December 10, 2002
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Jo Ann Marie Canich, George Alan Vaughan, Phillip T. Matsunaga, David Edward Gindelberger, Timothy Daniel Shaffer, Kevin Richard Squire
  • Patent number: 6486089
    Abstract: The invention relates to a process for uniformly dispersing a transition metal metallocene complex on a carrier comprising (1) providing silica which is porous and has a particle size of 1 to 250 microns, having pores which have an average diameter of 50 to 500 Angstroms and having a pore volume of 0.5 to 5.0 cc/g; (2) slurrying the silica in an aliphatic solvent having a boiling point less than 110° C.; (3) providing a volume of a solution comprising metallocene and alumoxane wherein the volume of solution is less than that required to form a slurry of the silica, wherein the concentration of alumoxane, expressed as Al weight percent, is 5 to 20; (4) contacting the silica slurry (2) with said volume of said solution (3) and allowing the solution to impregnate the pores of silica and, to disperse the metallocene in and on the carrier; (5) evaporating the solvents from the contacted and impregnated silica to recover dry free-flowing catalyst particles.
    Type: Grant
    Filed: November 9, 1995
    Date of Patent: November 26, 2002
    Assignee: ExxonMobil Oil Corporation
    Inventors: Yury V. Kissin, Robert I. Mink, Thomas E. Nowlin, Pradeep P. Shirodkar, Sandra D. Schregenberger, Grace O. Tsien
  • Patent number: 6476171
    Abstract: A polymer of ethylene and at least one alpha olefin having at least 5, carbon atoms obtainable by a continuous gas phase polymerization using supported catalyst of an activated molecularly discrete catalyst such as a metallocene in the substantial absence of an aluminum alkyl based scavenger which polymer has a Melt Index (MI) as herein defined of from 0.1 to 15; a Compositional Distribution Breadth Index (CDBI) as defined herein of at least 70%, a density of from 0.910 to 0.930 g/ml; a Haze value as herein defined of less than 20%; a Melt Index ratio (MIR) as herein defined of from 35 to 80; an averaged Modulus (M) as herein defined of from 20 000 to 60 000 psi (pounds per square inch) and a relation between M and the Dart Impact Strength in g/mil (DIS) complying with the formula: DIS≧0.8×[100+e(11.71-0.000268×M+2.183×10−9×M2)].
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: November 5, 2002
    Assignee: ExxonMobil Chemical Patents Inc.
    Inventors: Ching-Tai Lue, Natalie A. Merrill, Michael E. Muhle, George Alan Vaughan
  • Patent number: 6458910
    Abstract: Blown films of linear low density polyethylene are produced by a high stalk process comprising extruding the linear low density polyethylene through an annular die to form an extruded tube of molten material, cooling the extruded tube while drawing the tube so cooled, to maintain the tube diameter identical to that of the annular die and expanding the tube or bubble to attenuate the walls thereof by introducing a gas to the interior of the tube or bubble. The resulting films are characterized by superior impact strength and MD tear resistance.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: October 1, 2002
    Assignee: ExxonMobil Oil Corporation
    Inventors: Vaseem Firdaus, Pradeep P. Shirodkar
  • Patent number: H2058
    Abstract: The present invention provides cocatalysts for activating metallocene complexes in olefin polymerization reactions, and metallocene catalyst systems using the cocatalysts. The cocatalysts of the present invention include: (a) a halo-organoaluminum compound of the formula AlnRmX3n-m, where Al is aluminum, each R is independently a Cl to C4 alkyl group, X is a halide, n is 1 or 2, and m is determined by the valency of Al; and (b) a dialkylmagnesium compound of the formula MgR′2, where Mg is magnesium and R′ is a C2 to C6 alkyl group. The components (a) and (b) are used in amounts such that the molar ratio of Al:Mg is at least 2, preferably from 2:1 to 5:1.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: January 7, 2003
    Assignee: Mobil Oil Corporation
    Inventors: A. J. Brandolini, Yury Viktorovich Kissin, Robert Ivan Mink, Thomas E. Nowlin